BluePath Capital Management’s Pfizer PFE Stock Holding History

BluePath Capital Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,359	Closed	-$45.1K	–	267
2023 Q3	$45.1K	Buy	+1,359	New	+$48.1K	0.04%	191

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

BluePath Capital Management's PFE Position: Q4 2023 in Review

BluePath Capital Management sold out of Pfizer (PFE) in Q4 2023, closing a stake of 1,359 shares — an estimated $45.1K sold.

BluePath Capital Management first reported a position in PFE in Q3 2023 and held it in 1 quarter. The position peaked at $45.1K in Q3 2023. 2,936 funds tracked by Wall St. Rank hold PFE as of Q4 2023.

BluePath Capital Management reported no remaining Pfizer position as of Q4 2023 after selling out during the quarter.
BluePath Capital Management sold 1,359 Pfizer shares in Q4 2023, an estimated $45.1K.
BluePath Capital Management first reported a position in Pfizer in Q3 2023 and held it in 1 quarter.
BluePath Capital Management's Pfizer position peaked at $45.1K in Q3 2023.
2,936 funds tracked by Wall St. Rank held Pfizer as of Q4 2023.

Based on BluePath Capital Management's 13F filing for Q4 2023, filed 11 Jan 2024.